PainChek Ltd (AU:PCK) has released an update.
PainChek Ltd announces a significant milestone with 90,000 global licenses, marking a 40% year-on-year growth, notably achieving 30,000 in the UK, reflecting strong international demand for its pain assessment technology. The company has seen a steady increase in licenses, an 88% retention rate, and a successful $5 million capital raise, positioning it for further expansion including a planned entry into the US market following FDA clearance. PainChek’s continued growth is supported by a $1.2 million R&D tax incentive refund, with a total of 5 million pain assessments conducted using their technology.
For further insights into AU:PCK stock, check out TipRanks’ Stock Analysis page.
